Register for our free email digests:
Mitsubishi Tanabe Pharma Corporation
http://www.mt-pharma.co.jp/e/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mitsubishi Tanabe Pharma Corporation
Roche Returns To Cystic Fibrosis Fray With Enterprise Deal
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
Amylyx Drug Slows ALS Progression, Filings Imminent
Amylyx has raised just $75m to date, but that was enough to develop AMX0035 through a Phase II/III trial in which the drug slowed the progression of amyotrophic lateral sclerosis versus placebo.
Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- BIXEN Corporation
- Medicago Inc.
- Mitsubishi Tanabe Pharma America, Inc. (MTPA)
- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
- Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
- NeuroDerm, Ltd. (NDRM)
- PT Mitsubishi Tanabe Pharma Indonesia
- Mitsubishi Tanabe Pharma (Thailand)
- MT Pharma Singapore PTE. Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- Tanabe Research Laboratories U.S.A.